PPPutu Mirah Wahyu Subagia Putri

Putu Mirah Wahyu Subagia Putri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Putu Mirah Wahyu Subagia Putri has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EFFICACY AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELL (CAR-T) THERAPY IN LYMPHOMA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS

    by I Gede Krisna Arim Sadeva, I Gede Wikania Wira Wiguna, Ni Wayan Armerinayanti, Putu Mirah Wahyu Subagia Putri, Christo Timothy Mamangdean, Putu Ari Shanti Dewi, Kadek Meryndha Kumala Tungga, I Komang Raditya Putra Pratama, Agung Brahmanthya Nadine Kepakisan, Komang Indra Parama Arta

    Background: Lymphoma (Hodgkin and non-Hodgkin) is a malignancy of the lymphatic system, with global prevalence reaching 2.8% and mortality rates reaching 248,700 cases each year. Therefore, Chimeric Antigen Receptor-Modified T cell therapy (CAR-T) was developed as a new approach to improve survival rates in lymphoma patients. Objective: This study aimed to evaluate the efficacy and safety of CAR-T cell therapy in lymphoma. Methods: PRISMA 2020 was used in the literature search and systematic review with the keywords "CAR-T Cell Therapy" and "Lymphoma". All statistical analyses were performed with R statistical software version 3.3 and MedCalc software version 22. A p-value ≤ 0.05 was considered statistically significant. Results: There were 16 studies involving 440 patients with lymphoma. The complete response rate was 62% (95% CI 55%-65%, I² = 40%). Meanwhile, cytokine release syndrome (CRS) occurred in 73% of cases (95% CI 49%-88%, I² = 80%). The overall Immune effector cell-associated neurotoxicity syndrome (ICANS) rate was 17% (95% CI 9%-30%, I² = 66%). There is no significant publication bias in all analyses (p-value>0.05). However, these results need to be interpreted with caution, considering the high heterogeneity in the pooled analysis results (I² > 50%).